
FDA Gives Guidance on Development of Breast Cancer Drugs
The guidance provides recommendations for including premenopausal women in breast cancer clinical trials.
FDA published
The guidance does not address fertility and fertility preservations issues when treating premenopausal women with breast cancer. The agency recommends that a gynecologist be consulted during trial planning and monitoring.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.